Letermovir

Independent reference data for Letermovir (CAS 917389-32-3), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Letermovir is indicated for prophylaxis against cytomegalovirus (CMV) infection and disease in recipients, ≥6 months of age and ≥6 kg, of an allogeneic hematopoietic stem cell transplant (HSCT) who are CMV-seropositive. It is also indicated for prophylaxis against CMV disease in kidney transplant recipients, ≥12 years of age and ≥40 kg, who are at risk (i.e. donor CMV-seropositive/recipient CMV-seronegative).Letermovir is an antiviral agent which targets the DNA terminal transferase complex of the cytomegalovirus (CMV) and which is used to prevent CMV reactivation in immunocompromised patients. Letermovir has been associated with mild-to-moderate serum aminotransferase elevations during therapy but has not been linked to cases of clinically apparent acute liver injury.

Synonyms and trade names

Letermovir; 917389-32-3; Prevymis; AIC246; AIC-246; AIC 246; MK-8228; 1H09Y5WO1F; DTXSID40238683; letermovirum; RefChem:57199; DTXCID90161174; J05AX18; 805-689-9; UNII-1H09Y5WO1F; MFCD22572725

GHS hazard classification

Reported hazard statements	H361 (97.2%), H373 (100%)

H361 (97.2%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

H373 (100%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]

What the public record says

Letermovir · CAS 917389-32-3 · C29H28F4N4O4. UNII 1H09Y5WO1F.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.